Abstract: Systems and methods of the various embodiments may provide low cost bifunctional air electrodes. Various embodiments may provide a bifunctional air electrode, including a metal substrate and particles of metal and/or metal oxide catalyst and/or metal nitride catalyst coated on the metal substrate. Various embodiments may provide a bifunctional air electrode, including a first portion configured to engage an oxygen reduction reaction (ORR) in a discharge mode and a second portion configured to engage an oxygen evolution reaction (OER) in a charge mode. Various embodiments may provide a method for making an air electrode including coating a metal substrate with particles of metal and/or metal oxide catalyst and/or metal nitride catalyst. Various embodiments may provide batteries including air electrodes.

Abstract: The invention relates to Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide of general formula (I) which are inhibitors of phosphodiesterase 2, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.

Abstract: Systems and method for optimal control of one or more energy storage systems are provided. Based on live, historical, and/or forecast data received from one or more data sources, one or more forecasts of one or more parameters relating to the operation of the one or more energy storage systems and an associated forecast uncertainty may be calculated by various forecasting techniques. Using one or more optimization techniques, an optimal dispatch schedule for the operation of the one or more energy storage systems may be created based on the forecasts. The optimal dispatch schedule may be used to determine one or more energy storage system parameters, which are used to control the operation of the energy storage systems.

Abstract: This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, R1, R2, R3, R4, R5, R6 and R7 have meanings given in the description.

Abstract: This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar1 and Ar2 have meanings given in the description.

Abstract: Systems and methods for optimal control of one or more energy storage systems are provided. Based on live, historical, and/or forecast data received from one or more data sources, one or more forecasts of one or more parameters relating to the operation of the one or more energy storage systems and an associated forecast uncertainty may be calculated by various forecasting techniques. Using one or more optimization techniques, an optimal dispatch schedule for the operation of the one or more energy storage systems may be created based on the forecasts. The optimal dispatch schedule may be used to determine one or more energy storage system parameters, which are used to control the operation of the energy storage systems.

Abstract: The present invention relates to novel N-[(Pyrimidinylamino)propanyl]-, N-[(Pyridylamino)propanyl]- and N-[(Pyrazinylamino)propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.

Abstract: The present invention relates to novel N-[(Pyrimidinylamino)propanyl]- and N-[(Pyridinylamino)propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.

Abstract: Systems and methods for optimal planning and real-time control of energy storage systems for multiple simultaneous applications are provided. Energy storage applications can be analyzed for relevant metrics such as profitability and impact on the functionality of the electric grid, subject to system-wide and energy storage hardware constraints. The optimal amount of storage capacity and the optimal operating strategy can then be derived for each application and be prioritized according to a dispatch stack, which can be statically or dynamically updated according to data forecasts. Embodiments can consist of both planning tools and real-time control algorithms.

Abstract: 3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4.

Abstract: This invention relates to compounds of formula I a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, R1, R2 and R3 have meanings given in the description.

Abstract: The invention relates to morpholine and 1,4-oxazepane amide derivatives of general formula (I), which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture of the compounds according to the invention.

Abstract: Systems and methods for optimal planning and real-time control of energy storage systems for multiple simultaneous applications are provided. Energy storage applications can be analyzed for relevant metrics such as profitability and impact on the functionality of the electric grid, subject to system-wide and energy storage hardware constraints. The optimal amount of storage capacity and the optimal operating strategy can then be derived for each application and be prioritized according to a dispatch stack, which can be statically or dynamically updated according to data forecasts. Embodiments can consist of both planning tools and real-time control algorithms.

Abstract: The invention relates to Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide of general formula (I) which are inhibitors of phosphodiesterase 2, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.

Abstract: Various embodiments provide a battery, a bulk energy storage system including the battery, and/or a method of operating the bulk energy storage system including the battery. In various embodiment, the battery may include a first electrode, an electrolyte, and a second electrode, wherein one or both of the first electrode and the second electrode comprises direct reduced iron (“DRI”). In various embodiments, the DRI may be in the form of pellets. In various embodiments, the pellets may comprise at least about 60 wt % iron by elemental mass, based on the total mass of the pellets. In various embodiments, one or both of the first electrode and the second electrode comprises from about 60% to about 90% iron and from about 1% to about 40% of a component comprising one or more of the materials selected from the group of SiO2, Al2O3, MgO, CaO, and TiO2.

Abstract: Systems and methods of the various embodiments may provide metal air electrochemical cell architectures. Various embodiments may provide a battery, such as an unsealed battery or sealed battery, with an open cell arrangement configured such that a liquid electrolyte layer separates a metal electrode from an air electrode. In various embodiments, the electrolyte may be disposed within one or more vessel of the battery such that electrolyte serves as a barrier between a metal electrode and gaseous oxygen. Systems and methods of the various embodiments may provide for removing a metal electrode from electrolyte to prevent self-discharge of the metal electrode. Systems and methods of the various embodiments may provide a three electrode battery configured to operate each in a discharge mode, but with two distinct electrochemical reactions occurring at each electrode.

Abstract: Systems and methods of the various embodiments may provide a battery including a rolling diaphragm configured to move to accommodate an internal volume change of one or more components of the battery. Systems and methods of the various embodiments may provide a battery housing including a rolling diaphragm seal disposed between an interior volume of the battery and an electrode assembly within the battery. Various embodiments may provide an air electrode assembly including an air electrode supported on a buoyant platform such that the air electrode is above a surface of a volume of electrolyte when the buoyant platform is floating in the electrolyte.

Abstract: An electrochemical cell and battery system including cells, each cell including a catholyte, an anolyte, and a separator disposed between the catholyte and anolyte and that is permeable to the at least one ionic species (for example, a metal cation or the hydroxide ion). The catholyte solution includes a ferricyanide, permanganate, manganate, sulfur, and/or polysulfide compound, and the anolyte includes a sulfide and/or polysulfide compound. These electrochemical couples may be embodied in various physical architectures, including static (non-flowing) architectures or in flow battery (flowing) architectures.

Abstract: The invention relates to Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide of general formula (I) which are inhibitors of phosphodiesterase 2, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.

Abstract: A method for encapsulating photovoltaic cells into single functional units is described. These units share the mechanical and electric properties of the encapsulation layers and allow for flexible module architecture to be implemented at the cell level. This enables cost reduction and improved performance of photovoltaic power generation.